Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips

Absci reported Q1 2026 revenue of $200,000 versus $1.43 million expected, an 84.97% miss, though EPS of -$0.19 slightly beat the -$0.1943 consensus. Shares fell 3.11% after hours to $5.89 as investors weighed the revenue shortfall against continued R&D progress on ABS-201 and a cash runway into the first half of 2028. Management reiterated a data-heavy 2026 outlook, including next-month safety/PK data, 2H26 interim hair-growth readouts, and a planned Q4 start for the endometriosis trial.

Analysis

The market is likely still underpricing the optionality in the pipeline while over-focusing on the revenue miss, which is economically irrelevant for a clinical-stage name. The real value driver is whether the next two data windows validate a platform thesis: if early PK/safety lands cleanly and the 13-week signal is even directionally positive, the stock can re-rate on probability of success rather than current fundamentals. That makes this more of a binary event chain over the next 4-8 months than a traditional quarterly earnings story.

The hidden second-order effect is capital allocation discipline. By walking away from lower-fit oncology work, management is signaling that internal cash is now being reserved for programs with the highest strategic leverage and the best shot at non-dilutive partnering. That should improve runway quality even if it doesn’t change runway length, and it increases the odds of a portfolio of smaller licensing deals rather than one large platform transaction.

The main risk is not the quarter; it is proof-of-mechanism slippage. If the June PK update or the 2H26 interim hair readout disappoints, the market will likely compress the multiple quickly because the current valuation already embeds meaningful belief in differentiated dosing and category creation. Conversely, the contrarian read is that consensus may be too anchored to commercial hair-growth benchmarks and not giving enough credit to a durable, infrequent-dose profile; in this setup, “good enough” efficacy with clean safety may be sufficient to unlock a much larger TAM than the market expects.

Key Decisions for Investors

• Trade the catalyst, not the quarter: buy near-dated ABSI call spreads into the June PK/safety update and reduce into the print if the stock gaps up 10%+; risk/reward is favorable because a clean dose-frequency read could reprice the asset before efficacy data.
• Pair trade: long ABSI vs short a profitable biotech cash burner with no near-term clinical catalyst over the next 1-2 quarters; ABSI has a defined event path, while the short leg carries more balance-sheet and execution risk.
• If already long ABSI, hedge with out-of-the-money puts into the 2H26 interim efficacy window; the binary downside from a weak directional hair signal is larger than the downside from a mediocre earnings print.
• Watch for a post-update momentum entry only if PK/safety is clean and the market starts to price the 2027 full readout as the real decision point; that setup favors adding on confirmation rather than anticipating the move.
• Avoid chasing the stock on headline pipeline expansion alone; ABSI is likely to trade on evidence quality, so the right exposure is event-driven and size-limited until the first human data de-risks the platform.